Clarithromycin resistance in Helicobacter pylori: Prevalence in untreated dyspeptic patients and stability in vitro

被引:74
作者
Xia, HX
Buckley, M
Keane, CT
OMorain, CA
机构
[1] ST JAMES HOSP,CPL,DEPT CLIN MICROBIOL,DUBLIN 8,IRELAND
[2] MEATH HOSP,DEPT GASTROENTEROL,TRINITY COLL,DUBLIN 8,IRELAND
[3] ADELAIDE HOSP,TRINITY COLL,DUBLIN 8,IRELAND
关键词
D O I
10.1093/jac/37.3.473
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Susceptibilities to clarithromycin and metronidazole of 444 Helicobacter py(ori isolates cultured from antral biopsies of 444 dyspeptic patients were determined by disc diffusion tests (15 mu g disc for clarithromycin, 5 mu g disc for metronidazole). Susceptibility of 46 of these isolates to erythromycin (5 mu g disc) was also tested. Minimal inhibitory concentrations (MICs) of clarithromycin for 42 selected isolates were determined by a plate dilution method. A zone diameter of 30 mm was defined as a 'cut-off' size differentiating susceptibility and resistance of the organism to clarithromycin, by comparing results obtained with the two methods. Of the 444 isolates, 424 (95.5%) were highly sensitive to clarithromycin, with zone diameters ranging from 30 to 98 mm. Twenty isolates (4.5%) were defined as resistant to clarithromycin, with zone diameters ranging between 6 and 28 mm. The incidence of clarithromycin resistance was similar in men and women and in different age groups, and was not significantly different between patients with peptic ulcer and non-ulcer dyspepsia. Among the 444 isolates, 168 (37.8%) were metronidazole resistant. There was cross resistance between clarithromycin and erythromycin, but not between clarithromycin and metronidazole. Stability of clarithromycin resistance was evaluated by the disc diffusion test and confirmed by the plate dilution method. Among the 20 clarithromycin-resistant isolates, nine (45%) reverted to be sensitive after 2-5 subcultures on drug-free agar. The findings in this study indicate that the incidence of clarithromycin-resistant H. pylori in untreated dyspeptic patients is low. Cross-resistance occurs between macrolides and resistance to clarithromycin in some strains is reversible.
引用
收藏
页码:473 / 481
页数:9
相关论文
共 31 条
  • [1] DISK SUSCEPTIBILITY TESTING FOR CLARITHROMYCIN
    ANDREWS, J
    WISE, R
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1993, 12 (12) : 972 - 974
  • [2] SHORT-TERM LOW-DOSE TRIPLE THERAPY FOR THE ERADICATION OF HELICOBACTER-PYLORI
    BAZZOLI, F
    ZAGARI, RM
    FOSSI, S
    POZZATO, P
    ALAMPI, G
    SIMONI, P
    SOTTILI, S
    RODA, A
    RODA, E
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1994, 6 (09) : 773 - 777
  • [3] BELL GD, 1992, ALIMENT PHARM THERAP, V6, P427
  • [4] COGHLAN JG, 1987, LANCET, V2, P1109
  • [5] GLUPCZYNSKI Y, 1990, AM J GASTROENTEROL, V85, P1545
  • [6] TIGHT-BINDING OF CLARITHROMYCIN, ITS 14-(R)-HYDROXY METABOLITE, AND ERYTHROMYCIN TO HELICOBACTER-PYLORI RIBOSOMES
    GOLDMAN, RC
    ZAKULA, D
    FLAMM, R
    BEYER, J
    CAPOBIANCO, J
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (07) : 1496 - 1500
  • [7] CLARITHROMYCIN FOR THE ERADICATION OF HELICOBACTER-PYLORI
    GRAHAM, DY
    OPEKUN, AR
    KLEIN, PD
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 1993, 16 (04) : 292 - 294
  • [8] FACTORS INFLUENCING THE ERADICATION OF HELICOBACTER-PYLORI WITH TRIPLE THERAPY
    GRAHAM, DY
    LEW, GM
    MALATY, HM
    EVANS, DG
    EVANS, DJ
    KLEIN, PD
    ALPERT, LC
    GENTA, RM
    [J]. GASTROENTEROLOGY, 1992, 102 (02) : 493 - 496
  • [9] ENHANCEMENT OF THE INVITRO AND INVIVO ACTIVITIES OF CLARITHROMYCIN AGAINST HAEMOPHILUS-INFLUENZAE BY 14-HYDROXY-CLARITHROMYCIN, ITS MAJOR METABOLITE IN HUMANS
    HARDY, DJ
    SWANSON, RN
    RODE, RA
    MARSH, K
    SHIPKOWITZ, NL
    CLEMENT, JJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (07) : 1407 - 1413
  • [10] COMPARATIVE INVITRO ACTIVITIES OF NEW 14-MEMBERED, 15-MEMBERED, AND 16-MEMBERED MACROLIDES
    HARDY, DJ
    HENSEY, DM
    BEYER, JM
    VOJTKO, C
    MCDONALD, EJ
    FERNANDES, PB
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (11) : 1710 - 1719